LDLR and neoplasm: Although the function of PCSK9 in binding with LDLR to reduce LDL uptake has been recognized, its involvement in promoting tumor development primarily seems to revolve around the anti‐tumor immunity pathway or negative feedback to activate cholesterol synthesis.